1. Home
  2. GBIO vs RDI Comparison

GBIO vs RDI Comparison

Compare GBIO & RDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GBIO
  • RDI
  • Stock Information
  • Founded
  • GBIO 2016
  • RDI 1937
  • Country
  • GBIO United States
  • RDI United States
  • Employees
  • GBIO N/A
  • RDI N/A
  • Industry
  • GBIO Biotechnology: Pharmaceutical Preparations
  • RDI Movies/Entertainment
  • Sector
  • GBIO Health Care
  • RDI Consumer Discretionary
  • Exchange
  • GBIO Nasdaq
  • RDI Nasdaq
  • Market Cap
  • GBIO 29.2M
  • RDI 30.6M
  • IPO Year
  • GBIO 2020
  • RDI N/A
  • Fundamental
  • Price
  • GBIO $0.39
  • RDI $1.33
  • Analyst Decision
  • GBIO Strong Buy
  • RDI Hold
  • Analyst Count
  • GBIO 4
  • RDI 1
  • Target Price
  • GBIO $7.33
  • RDI $2.40
  • AVG Volume (30 Days)
  • GBIO 1.1M
  • RDI 33.2K
  • Earning Date
  • GBIO 08-06-2025
  • RDI 08-13-2025
  • Dividend Yield
  • GBIO N/A
  • RDI N/A
  • EPS Growth
  • GBIO N/A
  • RDI N/A
  • EPS
  • GBIO N/A
  • RDI N/A
  • Revenue
  • GBIO $24,556,000.00
  • RDI $205,644,000.00
  • Revenue This Year
  • GBIO N/A
  • RDI $7.47
  • Revenue Next Year
  • GBIO N/A
  • RDI $13.22
  • P/E Ratio
  • GBIO N/A
  • RDI N/A
  • Revenue Growth
  • GBIO 146.47
  • RDI N/A
  • 52 Week Low
  • GBIO $0.30
  • RDI $1.17
  • 52 Week High
  • GBIO $3.65
  • RDI $1.89
  • Technical
  • Relative Strength Index (RSI)
  • GBIO 52.02
  • RDI 50.93
  • Support Level
  • GBIO $0.32
  • RDI $1.24
  • Resistance Level
  • GBIO $0.36
  • RDI $1.31
  • Average True Range (ATR)
  • GBIO 0.03
  • RDI 0.06
  • MACD
  • GBIO 0.00
  • RDI -0.00
  • Stochastic Oscillator
  • GBIO 81.00
  • RDI 62.50

About GBIO Generation Bio Co.

Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

About RDI Reading International Inc

Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.

Share on Social Networks: